Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;37(8):581-96.
doi: 10.1007/s40264-014-0194-3.

A comparison of active adverse event surveillance systems worldwide

Affiliations
Review

A comparison of active adverse event surveillance systems worldwide

Yu-Lin Huang et al. Drug Saf. 2014 Aug.

Abstract

Post-marketing drug surveillance for adverse drug events (ADEs) has typically relied on spontaneous reporting. Recently, regulatory agencies have turned their attention to more preemptive approaches that use existing data for surveillance. We conducted an environmental scan to identify active surveillance systems worldwide that use existing data for the detection of ADEs. We extracted data about the systems' structures, data, and functions. We synthesized the information across systems to identify common features of these systems. We identified nine active surveillance systems. Two systems are US based-the FDA Sentinel Initiative (including both the Mini-Sentinel Initiative and the Federal Partner Collaboration) and the Vaccine Safety Datalink (VSD); two are Canadian-the Canadian Network for Observational Drug Effect Studies (CNODES) and the Vaccine and Immunization Surveillance in Ontario (VISION); and two are European-the Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical Records and Biomedical Knowledge (EU-ADR) Alliance and the Vaccine Adverse Event Surveillance and Communication (VAESCO). Additionally, there is the Asian Pharmacoepidemiology Network (AsPEN) and the Shanghai Drug Monitoring and Evaluative System (SDMES). We identified two systems in the UK-the Vigilance and Risk Management of Medicines (VRMM) Division and the Drug Safety Research Unit (DSRU), an independent academic unit. These surveillance systems mostly use administrative claims or electronic medical records; most conduct pharmacovigilance on behalf of a regulatory agency. Either a common data model or a centralized model is used to access existing data. The systems have been built using national data alone or via partnership with other countries. However, active surveillance systems using existing data remain rare. North America and Europe have the most population coverage; with Asian countries making good advances.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Types of databases used in worldwide active surveillance systems. The Federal Partners Collaboration and Mini-Sentinel are counted separately, and systems may use multiple types of databases. EHR electronic health records, PBM pharmacy benefits manager
Fig. 2
Fig. 2
Characteristics of data elements used in worldwide surveillance systems. The Federal Partners Collaboration and Mini-Sentinel are counted separately. The percentage of each data element is calculated based on available data in each category. Additionally, vaccination surveillance systems were not calculated in “drug codes” and “quantity”
None

References

    1. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824–829. doi: 10.1001/jama.281.9.824. - DOI - PubMed
    1. Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol. 2001;28:1180–1187. - PubMed
    1. Department of Health and Human Services/US Food and Drug Administration. IND Safety Reports. 21 The Code of Federal Regulations. 312.32; 2013.
    1. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–396. doi: 10.2165/00002018-200629050-00003. - DOI - PubMed
    1. Harmark L, van Grootheest K. Web-based intensive monitoring: from passive to active drug surveillance. Expert Opin Drug Saf. 2012;11:45–51. doi: 10.1517/14740338.2012.629184. - DOI - PubMed